# ANTO Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anto-therapeutics

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Latest round: Angel (Sep 27, 2025)
- Investors on record: 4

## About

Founded in 2023 and based in Wuxi, China, ANTO Therapeutics is a biotechnology company that focuses on the production of vivo lentiviral vector-based gene therapy drugs. It cooperated with research institutions, tertiary hospitals, and CROs (Contract customization research and development institutes). The team members have biomedical technology and industrial management experience. In September 2025, ANTO Therapeutics closed an angel+ funding from new investor FIRHealth Capital.

ANTO Therapeutics is a gene therapy and innovative delivery technology platform. The platform engages in vivo lentiviral vector-based gene therapy innovative drug programs. It has developed a fifth-generation lentiviral vector (5G vector) platform for in vivo gene therapy. Its product pipeline focuses on drugs for solid tumors and neurological tumors.

The company generates revenue through develop lentiviral vector-based gene therapy innovative drug programs and sales of drugs for solid tumors and neurological tumors.

The company will continue to develop its lentiviral gene therapy pipeline.

## Funding rounds

- Angel, Sep 27, 2025 — FIRHealth Capital
- Angel, Dec 29, 2023 — Triwise Capital, Transfar Group, Shanghai INT Medical Instruments

## Investors

- Triwise Capital (https://capitalatlas.ai/funds/triwise-capital) — Angel
- Transfar Group — Angel
- Shanghai INT Medical Instruments — Angel
- FIRHealth Capital (https://capitalatlas.ai/funds/firhealth-capital) — Angel